'Abbreviations used in this paper: DFP, diisopropylfluorophosphate; DIC, disseminated intravascular, coagulation; GEE-"C, glycine ethyl ester-"C; SBTI, soybean trypsin inhibitor. clotting factors. Were it possible to measure soluble, thrombin-altered fibrinogen (circulating fibrin), the diagnosis and management of DIC could be based on the primary abnormality. For this purpose, a method for measuring circulating fibrin was designed which depends upon the enzymatic incorporation of glycine ethyl ester-"C (GEE-QC) into fibrin.
Lorand and Ong (1) incorporated GEE-'4C into purified fibrin with activated factor XIII, a fibrin-stabilizing enzyme. In the present studies, factor XIII and GEE-"C were added to an 8% ethanol fraction of human plasma and the amount of GEE-"C incorporation in the clottable portion of this fraction measured. Applying this technique to in vitro and in vivo experiments revealed that an increase in incorporation occurred when thrombinaltered fibrinogen (circulating fibrin) was present, but no increase was detected when plasmin-digested fibrinogen (fibrinogen split products) were present unless the split products were also exposed to thrombin. The presence of plasmin-digested fibrin (fibrin split products) increased the incorporation only slightly at high concen- trations.
METHODS
Preparation of plasma. GEE-1Ca (3.04 mCi/mmole), crude streptokinase,' and hirudin' were obtained commercially. The hirudin concentration was standardized acccording to the method of Rapaport (2) . Blood for-measurement of circulating fibrin was drawn by venepuncture into a plastic syringe and nine parts of blood were added to a conical 15 ml polystyrene centrifuge tube' containing one part of an anticoagulant mixture consisting of 2%o EDTA, 10 U/ml hirudin, and 10 mg/ml soybean trypsin inhibitor (SBTI). The (4) . The earliest protein eluted contained fibrinogen free of factor XIII activity when tested by allowing the fibrinogen to clot for 1 hr in the presence of 2.5 NIH U/ml thrombin, 0.005 M cystine, 0.005 M calcium, 0.075 M KCL, and 0.5 mg/ml soybean trypsin inhibitor. This fibrinogen, once clotted, easily dissolved in 2% monochloracetic acid; the criterion for absent factor XIII activity.
Factor XIII was activated by incubating crude factor XIII in cysteine, calcium, and thrombin for 15 min at 37°C (see Table I ). The thrombin activity was quenched at the end of the activation period by adding diisopropylfluorophosphate9 (DFP), 5X 10-' M. The active factor XIII mixture was diluted in 0.02 M Tris, 0.15 M NaCl buffer, 0.05 M cysteine, 0.01 M CaC12, pH 7.4, to a concentration of 30 U/ml. This diluted activated factor XIII was used immediately in the reaction mixture for the labeling of circulating fibrin.
Labeling fibrin. An outline of the method for labeling the circulating fibrin in a plasma sample is presented in Table II . An 8% ethanol fraction of plasma was precipitated at 0°C for 1 hr from 0.8 ml of whole plasma with 0.2 ml 40%o ethanol in tris buffer, pH 7.4. The ethanol precipitate was washed once with 2 ml 8% ethanol at 0°C and dissolved in 0.8 ml of tris buffer, pH 7.4; 1 mg/ml SBTI, 1 U/ml hirudin. After addition of GEE-"4C, active factor XIII, and 0.25 M Tris, 0.05 M NaCl buffer, pH 8.2, to the fibrinogen fraction, the mixture was incubated for 30 min at room temperature after which time 0.1 ml of 0.25 M EDTA was added to stop the action of factor XIII. The fibrinogen fraction was again precipitated from this mixture in 8% ethanol. (9) and by the rapid heat precipitation method of Foster and coworkers (10) . Factors V and VIII were quantitated by measuring the ability of the test plasma to correct the coagulation defect in plasma deficient in these factors (11, 12) . The thrombin time was done as described by von Kaulla and von Kaulla (13) and the split products of fibrinogen in serum were detected on immunodiffusion of serum against antihuman fibrinogen" as described bv Merskey and coworkers (14) or by the use of the red cell hemaglutination inhibition assay (14) . The ethanol gel test was done by the method of Breen and Tullis (15) . Thrombin used in the experiments was bovine thrombin 12 purified by chromatography on IRC-50 as described by Rasmussen (16) . The specific activity of the purified preparation was 13,000 NIH U/mg protein.
RESULTS
Normal values. The mean values of amounts of GEE-4C incorporated into the 8% ethanol fraction of plasma 7.4 buffer). Neither a visible clot nor fibrin strands appeared during incubation. In a similar experiment, hirudin (1 U/ml) was added to plasma before incubation with thrombin in order to block the enzymatic activity of thrombin on fibrinogen. After incubation of this mixture for 15 min at room temperature, there was no increase in the incorporation of GEE-1"C (Table III) . When a plasma (No. 2, No. 4) not previously exposed to thrombin was mixed with a sample of that same plasma which had been exposed to thrombin, the increase in incorporation of GEE-1C was proportional to the quantity of thrombin-treated plasma in the mixture (Table IV) .
Urokinase-altered fibrinogen and fibrin. To exclude the possibility that fibrinogen or fibrin split products released by plasmin would significantly increase the incorporation of GEE-`C by plasma fibrinogen, plasma-containing fibrinogen and fibrin split products was tested for its capacity to incorporate GEE-'4C. When normal human citrate plasma was incubated with urokinase (500 CTA U/ml final concentration) at 370C for 18 hr, it was no longer clottable with thrombin. One-half of this plasma containing fibrinogen split products was then treated with thrombin (1 NIH U/ml final concentration) for 30 min. Both plasmas (thrombin-treated and untreated) containing fibrinogen split products were then added, nine parts of the plasma to one part SBTI, EDTA, hirudin (Fig. 2) . In this Figure wells 1 Mixtures of normal human plasma with plasma containing plasmin digestion products of fibrinogen and fibrin. X, normal human plasma; *, normal human plasma mixed with fibrinogen split products; *, normal human plasma mixed with thrombin-treated fibrinogen split products; A, normal human plasma mixed with fibrin split products.
mal human plasma. The incorporation of GEE-`4C into the fibrinogen in these mixtures was no greater than that in normal plasma alone (Fig. 3) . However, the mixture of normal plasma with 37.5% fibrinogen split products that had also been exposed to thrombin incorporated more GEE-54C (108 dpm/mg fibrinogen above the normal plasma alone). The GEE-1'C incorporation into the fibrinogen of normal plasma with 37.5% fibrin split products increased only 57 dpm/mg fibrinogen above the normal plasma. Therefore, plasmin-digested fibrinogen increased the incorporation of GEE-14C in normal plasma only after being hydrolyzed by thrombin, and plasmin-digested fibrin clot in normal plasma increased GEE-14C incorporation only minimally and only at high concentrations. Per cent recovery. As the concentration of fibrinogen or fibrin split products added to normal plasma was increased, the amount of clottable protein, which could be recovered from the mixtures decreased. When the concentration of fibrin split products was increased to 37.5, the per cent of fibrinogen recovered was only 18% of that expected. With concentrations greater than 37.5%, the 8% ethanol fraction was no longer clottable and recovery was therefore zero. However, provided the over-all recovery was 0.3 mg/ml of protein in the final 3 cc of 2% monochloracetic acid solution, variation in the recovery of fibrinogen from plasma was not related to changes in incorporation of GEE-1'C.
Dogs infused with thrombin. To evaluate the method for measuring circulating fibrin in vivo, two mongrel dogs were anesthetized with Penthrane ' and the saphenous veins of the hind limb and fore limb were cannulated with No. 19 scalp vein sets. Blood samples were withdrawn from the saphenous vein of the fore limb at varying time intervals before, during, and after continuous intravenous infusion of bovine thrombin into the hind linmb. In one experiment factors V and VIII were measured on the samples using plasma from humans severely congenitally deficient in each factor as substrate for determining the ability of the dog plasma to shorten their clotting times (11, 12) . Fibrinogen concentrations were determined by the method of Ratnoff and Menzie (9) and serum was tested for split products of fibrinogen by immunodiffusion (14) . When given an infusion of 1 NIH U/kg per min of bovine thrombin for 20 min, an early increase in the ability of the plasma from two dogs to incorporate GEE-14C into fibrinogen occurred and persisted for 1 hr after cessation of the infusion (Fig. 4) . Concentrations of factors V, VIII, and fibrinogen in the plasma of dog No. 4 decreased and split products were present toward the end of the 20 min thrombin infusion (Table V) .
Clinical observations. Two patients with bacteriologically proven meningococcemia were found to have circulating fibrin in association with other evidence suggesting disseminated intravascular coagulation (DIC). The first, patient A, was a 3i2 yr old girl admitted to the hospital with a temperature of 104'F, blood pressure 86/50, and a generalized petechial rash. The prothrombin time of her plasma was prolonged (15 sec; normal, 12 sec), but the partial thromboplastin time was normal (37 sec), as was the fibrinogen concentration measured by the heat precipitation method (190 mg/100 ml), and the number of platelets appeared normal on the blood smear. The ethanol gel test was negative. Circulating fibrin, however, was present, as indicated by a GEE-14C incorporation of 344 dpm/mg fibrinogen. 11 hr after the initiation of heparin therapy the level of GEE-14C incorporation had returned to normal, 188 dpm/ The second patient with meningococcemia, a 7 month old girl, was admitted to the hospital in a moribund condition with a temperautre of 1020C; blood pressure, 80/40; generalized petechiae and ecchymoses. She had received 250 U of heparin at another hospital before her admission to The Children's Hospital. Her fibrinogen GEE-14C incorporation was increased, 585 dpm/mg fibrinogen, and the ethanol gel test was positive. Heparin treatment was continued and 12 hr after admission GEE-'C incorporation had returned to normal, 129 dpm/mg fibrinogen. However, the patient had a cardiac arrest and died 16 hr after admission.
Two patients with Rocky Mountain spotted fever were studied. Plasma from both had prolonged prothrombin times (27.6 sec and 22.9 sec), prolonged partial thromboplastin times (70 sec and 67.2 sec), less than 50 mg/ 100 ml of fibrinogen by the heat precipitation method and low platelet counts (7,900 and 12,000/mm8). Neither patient had a positive ethanol gel test. In plasma from both patients, increased amounts of GEE-14C were incorporated (499.2 and 358.7 dpm/mg fibrinogen). Both patients recovered after therapy with antibiotics and heparin, and when GEE-14C incorporation was repeated 24 hr and 1 wk after admission, the amounts were within the normal range (222 and 129 dpm/mg fibrinogen).
Three patients, E, F, and G, were studied in whom therapeutic abortions were induced by the intrauterine injection of hypertonic saline. Details of these patients have been presented in a separate publication (17) . All three patients developed circulating fibrin after the intrauterine injection of saline as measured by GEE-1'C incorporation. One patient (E) with a retained dead fetus had increased GEE-14C incorporation before the injection of hypertonic saline. be inapparent, however, when the rate of synthesis or degree of activation of a clotting factor exceeds its rate of consumption. The present study was designed to evaluate a method for direct measurement of an effect of thrombin by measuring that portion of fibrinogen in plasma which has been converted to fibrin but remained soluble (circulating fibrin). Lorand and Ong (1) originally demonstrated the enzymatic incorporation of GEE-4C into fibrin. The method described in this manuscript is based upon theirs in which GEE-14C is incorporated into fibrin by the action of factor XIII.
In the method described, EDTA, hirudin, and SBTI were added to the plasma and the 8% ethanol fraction before and during the enzymatic incorporation of GEE-14C into fibrinogen to prevent any further proteolytic alterations of the fibrinogen once it had been removed from the patient. Since only the clottable portion of the 8% ethanol fraction of plasma was tested for incorporation of GEE-14C, it is not known whether other nonclottable proteins in this fraction may also incorporate the label. Under the conditions described, some incorporation occurred in the clottable protein portion of the 8% ethanol fraction in normal plasma (167 ±47 dpm/mg fibrinogen), as if there may be circulating fibrin in normal plasma. However, these studies do not exclude the possible incorporation of some GEE-14C by unaltered fibrinogen. When the amount of normal plasma was decreased so that the final yield of fibrinogen was less than 0.3 mg/ml (0.9 mg total), there was a progressive increase in the incorporation of the label. This finding suggests that increased incorporation of GEE-`4C in unaltered fibrinogen will occur at high enzyme to substrate concentrations. If the final yield of fibrinogen was 0.3 mg/ml or greater, no significant variation in labeling was found even though the over-all recovery of fibrinogen was only 18%. Though some incorporation may occur with unaltered fibrinogen, the presence of thrombinaltered fibrinogen (circulating fibrin) markedly increased the incorporation of GEE-14C. This effect was clearly evident when thrombin was added to normal plasma in vitro (Tables III and IV ) and in animal studies in which dogs were given continuous intravenous infusions of thrombin (Fig. 4) .
The ethanol gel test of Breen and Tullis (15) proposed as a specific measure for the presence of circulating fibrin was apparently not reliable in that it was often negative in the face of evidence that circulating fibrin was present as measured by GEE-14C incorporation. Moreover, plasma from the two patients with Rocky Mountain spotted fever and all three women after induced abortion had alterations of other clotting factors, including GEE-14C incorporation, consistent with the diagnosis of disseminated intravascular coagulation although the ethanol gel test was negative in all instances.
The possibility that plasmin-altered fibrinogen or fibrin niight increase GEE-14C incorporation was considered. Urokinase-induced split products of unclotted fibrinogen did not significantly increase the incorporation of the label when mixed with normal plasma unless these products were exposed to thrombin. Urokinase-induced split products from a fibrin clot when present at 37.5% concentration in normal plasma increased the labeling by only 57 dpm/mg fibrinogen. The appearance of split products in the serum of the dog infused with thrombin and in patients with DIC did not correlate with changes in GEE-14C incorporation. Thus the method is apparently insensitive to plasmin alterations of fibrinogen and fibrin.
The potential usefulness of the method for measuring circulating fibrin was shown in the patients studied. The first patient with meningococcemia had circulating fibrin as measured by GEE-14C. With heparin therapy, the GEE-'C labeling of fibrinogen returned to normal, suggesting that the patient suffered an episode of disseminated intravascular coagulation which improved on therapy with heparin. Other changes in clotting factor concentrations suggestive of disseminated intravascular coagulation were not, however, present in this patient. The three patients in whom intrauterine injection of hypertonic saline was used for the induction of therapeutic abortion all had circulating fibrin as measured by GEE-14C incorporation. The usual changes in coagulation factor concentrations associated with disseminated intravascular coagulation also occurred in these patients (Table VI) . The diagnosis of disseminated intravascular coagulation could therefore have ultimately been made by conventional methods, although increased GEE-14C incorporation preceded other changes. The method thus provides a sensitive tool for identifying circulating fibrin in DIC and should therefore aid in our understanding of this condition and its therapy.
